宝济药业-B（02659）首挂上市，公告显示，每股定价26.38港元，共发行3791.17万股股份，每手100 股，所得款项净额约9.22亿港元。截至发稿，股价上涨119.86%，现报58港元，成交额2.69亿港元。 招股书显示，宝济药业是一家处于临床和商业化阶段的生物技术公司，利用合成生物技术在中国开发及 提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。宝济药业通过技术差异 化的产品，勇闯四个独立且高价值的治疗市场，包括大容量皮下给药、抗体介导的自身免疫性疾病、辅 助生殖药物及重组生物制药取代传统生化产品的变革性产品。 来源：新浪港股 ...

北京商报讯（记者 丁宁）12月10日，宝济药业（02659.HK）登陆港交所，公司股票上市首日高开 129.34%，开盘价为60.5港元/股。 资料显示，宝济药业成立于2019年，是一家处于临床和商业化阶段的生物技术公司，利用基于合成生物 技术的先进生物制造在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的 目标病症。 ...

Group 1: IPO Activities - No companies listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange from August 18 to August 24 [2] - No companies passed the listing committee review during the same period on both exchanges [3] - No companies submitted listing applications on the Shanghai Stock Exchange and Shenzhen Stock Exchange [4] - One company terminated its listing review on the Shanghai Stock Exchange, while none did so on the Shenzhen Stock Exchange [5] Group 2: Hong Kong Stock Exchange Activities - One company was listed on the Hong Kong Stock Exchange during the period [7] - Tian Yue Advanced, a technology company focused on silicon carbide single crystal substrate materials, saw its stock price rise by 6.40% on the first day of trading, closing at HKD 45 per share, a 5.14% increase from the issue price of HKD 42.8, with a market capitalization of approximately HKD 32.9 billion [8] - Two companies initiated new stock offerings, with one completing the offering during the week [9] Group 3: Company Listings and Financial Data - Shuangdeng Co., Ltd. is a battery storage company specializing in lead-acid and lithium-ion storage batteries for communication base stations, data centers, and power storage [11] - Jiaxin International is a tungsten mining company based in Kazakhstan, focusing on the development of the Bakuta tungsten mine [12] Group 4: Recent IPO Filings - Star Ring Technology submitted its prospectus on August 18, aiming for a dual listing on the Hong Kong Stock Exchange and A-share market, focusing on AI infrastructure software [26] - Lixun Precision submitted its prospectus on August 18, also targeting a dual listing, and is a leading precision manufacturing technology company [29] - Huge Dental Limited (Hugao) submitted its prospectus on August 18, focusing on dental materials [32] - Zebra Intelligent submitted its prospectus on August 20, specializing in intelligent cockpit solutions [40] - Shenghong Technology submitted its prospectus on August 20, focusing on AI and high-performance computing PCBs [43] - Yingfa Ruineng submitted its prospectus on August 20, specializing in photovoltaic cell manufacturing [47] - Qianyuan Weike submitted its prospectus on August 21, focusing on coal logistics services [52] - Tianchen Biopharmaceutical submitted its prospectus on August 21, focusing on innovative drug development [56] - Shanghai Baoji Pharmaceutical submitted its prospectus on August 21, focusing on recombinant biopharmaceuticals [59] - Xinhua Xinjishu submitted its prospectus on August 22, providing software technology services [63] - Xiaoe Inc. submitted its prospectus on August 22, focusing on SaaS solutions for private domain operations [66] - Manycore Tech Inc. submitted its prospectus on August 22, specializing in cloud-native space design software [69] Group 5: Financial Performance - Star Ring Technology's revenue from 2022 to 2024 was CNY 373 million, CNY 491 million, and CNY 371 million, with losses of CNY 272 million, CNY 289 million, and CNY 344 million respectively [28] - Lixun Precision's revenue for the same period was CNY 214.03 billion, CNY 231.91 billion, and CNY 268.80 billion, with profits of CNY 10.49 billion, CNY 12.24 billion, and CNY 14.58 billion respectively [31] - Huge Dental's revenue was CNY 280 million, CNY 358 million, and CNY 399 million, with profits of CNY 64.03 million, CNY 88.35 million, and CNY 76.57 million respectively [34] - Zebra Intelligent's revenue was CNY 805 million, CNY 872 million, and CNY 824 million, with losses of CNY 878 million, CNY 876 million, and CNY 847 million respectively [42] - Shenghong Technology's revenue was CNY 7.88 billion, CNY 7.93 billion, and CNY 10.73 billion, with profits of CNY 791 million, CNY 671 million, and CNY 1.15 billion respectively [46] - Yingfa Ruineng's revenue was CNY 5.64 billion, CNY 10.49 billion, and CNY 4.36 billion, with profits of CNY 350 million, CNY 410 million, and losses of CNY 864 million respectively [51] - Qianyuan Weike's revenue was CNY 4.52 billion, CNY 3.74 billion, and CNY 3.66 billion, with profits of CNY 165 million, CNY 47 million, and CNY 33 million respectively [54] - Tianchen Biopharmaceutical's revenue was CNY 0 and losses of CNY 95.78 million and CNY 137 million for 2023 and 2024 respectively [58] - Shanghai Baoji Pharmaceutical's revenue was CNY 6.93 million and CNY 6.16 million, with losses of CNY 160 million and CNY 364 million respectively [61] - Xinhua Xinjishu's revenue was CNY 1.63 billion, CNY 1.93 billion, and CNY 1.80 billion, with profits of CNY 182 million, CNY 270 million, and CNY 202 million respectively [65] - Xiaoe Inc.'s revenue was CNY 299 million, CNY 415 million, and CNY 521 million, with losses of CNY 33.99 million, CNY 37.05 million, and CNY 15.08 million respectively [68] - Manycore Tech's revenue was CNY 601 million, CNY 664 million, and CNY 755 million, with losses of CNY 704 million, CNY 646 million, and CNY 513 million respectively [72]